

BLA 761055/S-042

## SUPPLEMENT APPROVAL

Regeneron Pharmaceuticals, Inc.  
Attention: Elisa Babilonia, PhD  
Senior Director, Regulatory Affairs  
777 Old Saw Mill River Rd  
Tarrytown, NY 10579

Dear Dr. Babilonia:

Please refer to your supplemental biologics license application (sBLA), dated and received December 9, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for DUPIXENT (dupilumab) injection.

This Prior Approval supplemental biologics license application provides for an extension of the age range for the atopic dermatitis indication to allow for the “treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.”

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,<sup>1</sup> that is identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to less than 6 months because necessary studies are impossible or highly impracticable.

We note that you have fulfilled the pediatric study requirement for ages 6 months to less than 18 years for this application.

### **FULFILLMENT OF POSTMARKETING REQUIREMENT(S)/COMMITMENT(S)**

Your submission dated December 9, 2021, contained the final report for the following postmarketing requirement listed in the March 28, 2017, approval letter for BLA 761055.

- 3183-4 Conduct a safety, pharmacokinetic (PK), and efficacy study in subjects 6 months to less than 6 years with severe atopic dermatitis.

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there are postmarketing requirements and a postmarketing commitment listed in the March 28, 2017, approval letter that are still open.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

## **REPORTING REQUIREMENTS**

We request that for a period of 2 years from the U.S. approval date of this sBLA, you submit all reported labeled and unlabeled serious adverse events (SAEs) (i.e., both 'serious and expected' or 'serious and unexpected' adverse events) with DUPIXENT (dupilumab) injection in patients aged  $\geq 6$  months to 2 years as 15-day expedited reports, and we request that you provide detailed analyses of these SAEs in the periodic safety report (i.e., the Periodic Adverse Drug Experience Report [PADER] required under 21 CFR 314.800(c)(2) or the ICH E2C Periodic Benefit-Risk Evaluation Report [PBRER] format). These analyses should include an assessment of the interval and cumulative adverse event reports for all labeled and unlabeled SAEs in patients  $\geq 6$  months to 2 years of age in your post-market safety database; reports from IND, non-IND, and NDA studies; and the medical literature. The summary should include the report narrative or the manufacturer control number if submitted to MedWatch.

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

If you have any questions, call Matthew White, Senior Regulatory Project Manager, at 301-796-4997.

Sincerely,

*{See appended electronic signature page}*

Tatiana Oussova, MD, MPH  
Deputy Director for Safety  
Division of Dermatology and Dentistry  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

TATIANA OUSSOVA  
06/07/2022 01:42:37 PM